OnKure Therapeutics, Inc.
OKURHeld by 6 specialist biotech funds
High Convergence6 funds opened new positions. Short interest: 0.7% of float.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.